You are here

Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 4R44CA265424-02
Agency Tracking Number: R44CA265424
Amount: $1,482,122.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: 102
Solicitation Number: PA20-260
Timeline
Solicitation Year: 2020
Award Year: 2022
Award Start Date (Proposal Award Date): 2022-09-01
Award End Date (Contract End Date): 2024-08-31
Small Business Information
CELDARA MEDICAL, LLC
Lebanon, NH 03766-1441
United States
DUNS: 828763263
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JOANA MURAD
 (617) 320-8521
 jm@celdaramedical.com
Business Contact
 JAKE REDER
Phone: (617) 320-8521
Email: jr@celdaramedical.com
Research Institution
N/A
Abstract

PROJECT SUMMARY
Cancer is one of the leading causes of death worldwide. Over the years, a number of conventional cytotoxic
approaches for neoplastic diseases has been developed. However, due to their limited effectiveness in
accordance with the heterogeneity of cancer cells, there is a constant search for therapeutic approaches with
improved outcome, such as immunotherapy that utilizes and enhances the normal capacity of the patient's
immune system. Of note, renal cell carcinoma and ovarian cancer are considered immunogenic, or “hot”
cancers, in that tumors are infiltrated with T cells. This provides optimism that the immune system can be
harnessed to be a potent and durable weapon against these cancers.
Chimeric antigen receptor (CAR) T-cell therapy represents a major advancement in personalized cancer
treatment. In this strategy, a patient's own T cells are genetically engineered to express a synthetic receptor
that binds a tumor antigen. We have developed a CAR T cell therapy, CM-CX1, designed to target a very
specific marker (TIM-1) in renal and ovarian cancers. Expression of TIM-1 in healthy tissues is limited to
absent. The goal of this Fast Track proposal is to finalize the preclinical work required for CM-CX1 filing of
an IND for first-in-human evaluation.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government